I agree there is a good story here, and the number of o/s is a big plus. It also appears that the drug actually works and is better than anything else out there, but that has been the case for years. The big hurdle, imo, is the FDA and big money. It has always seemed that approval is just out of reach and the goalpost keeps moving as those with the power allow the big companies to try and catch up. Then throw in the Russian connection. Looks like another battle between what should happen and what does happen.
Still very low volume.
News 
Market Data 
Discover 
